Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA
Ellipsis Health
Utilizes artificial intelligence to analyze vocal biomarkers for identifying signs of depression and anxiety.
What they do
Ellipsis Health develops machine learning software that analyzes brief voice recordings to assess patients for depression and anxiety. Used by health systems and payers, the diagnostic tool measures clinical symptom severity in real time, helping providers monitor mental health conditions continuously.
The record
- Vertical
- Mental & Behavioral Health
- Sub-segment
- Vocal biomarker diagnostics
- Product type
- Diagnostics
- Stage
- Series A
- Headquarters
- San Francisco, USA
- Region
- North America
- Founded
- 2015
- Total funding
- $30M raised
Notable investors: SJF Ventures, Greycroft, Luminate Health.
Also in Mental & Behavioral Health
Related on The Signal
Dr. Dereck Mush, MD, MBA
The $1 Billion Bet on Pre-Symptomatic Medicine: Who Will Own the Longitudinal Baseline?
Dr. Dereck Mush, MD, MBA
Decentralized and adaptive trial designs move from pilot to default in biotech development plans
Dr. Dereck Mush, MD, MBA
New diagnostic tools are trying to shrink endometriosis's decade long diagnosis gap
Dr. Dereck Mush, MD, MBA